Treatment of obesity and obesity-related disorders
US-2024277813-A1 · Aug 22, 2024 · US
Use of hepcidin as a regulator of iron homeostasis
US2016166649A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016166649-A1 |
| Application number | US-201514747926-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 23, 2015 |
| Priority date | May 25, 2001 |
| Publication date | Jun 16, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.
First claim
Opening claim text (preview).
1 - 13 . (canceled) 14 . A method for reducing iron overload in a patient in need thereof, comprising administering to said patient a polypeptide comprising a sequence of 20 amino acids having: at least 50% identity with the sequence SEQ ID NO: 1 cysteine residues at positions 2, 5, 6, 8, 9, 14, 17, and 18, and wherein the polypeptide is able to reduce iron absorption. 15 . A method according to claim 14 , wherein said polypeptide has at least 60% identity with the sequence SEQ ID NO: 1. 16 . A method according to claim 14 , wherein the polypeptide has at least 60% similarity with the sequence SEQ ID NO: 1. 17 . A method according to claim 14 , wherein the polypeptide has at least 70% similarity with the sequence SEQ ID NO: 1. 18 . A method according to claim 14 , wherein the polypeptide comprises the sequence SEQ ID NO: 1. 19 . A method according to claim 14 , wherein the polypeptide comprises the sequence SEQ ID NO: 2. 20 . A method according to claim 14 , wherein the polypeptide comprises the sequence SEQ ID NO: 3. 21 . A method according to claim 14 , wherein the polypeptide is a polypeptide of 25 amino acids having the sequence SEQ ID NO: 3. 22 . A method according to claim 14 , for treating hemochromatosis, or a disease resulting therefrom. 23 . A method according to claim 22 , wherein said disease resulting from hemochromatosis is hepatocarcinoma, cardiomyopathy, or diabetes. 24 . A method of according to claim 14 , for treating a disease selected from hepatocarcinoma, cardiomyopathy, or diabetes.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016166649A1 cover?
- The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med
- What technology area does this patent fall under?
- Primary CPC classification A61K38/22. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jun 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).